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Amyloid aggregation and neurofibrillary pathology is the characteristic feature of Alzheimer's disease (AD). Streptozotocin 
(STZ) is a glucosamine nitrosourea compound that is toxic to the cells, impairs insulin signaling in the brain. STZ induces 
DNA damage and oxidative stress, which leads to cognitive impairments. In this experimental study, STZ treatment induces 
Alzheimer's pathology in mouse neuroblastoma (N2A) cells. The study also explored the protection of cellular damage by 
pre-treatment with test drugs Apple cider vinegar (ACV), chrysin and rivastigmine. This study had been concentrated 
mainly on the cellular mechanism of neuromodulation and anti –oxidant potency of test drugs to attenuate cellular toxicity 
induced by STZ treatment. The 100 µM concentration of STZ was used for treatment in N2A cells for 24 h and 48 h and 
multiple studies were performed. The STZ causes tau phosphorylation, amyloid aggregation and increased acetyl 
cholinesterase (AChE) activity. Along with STZ at a concentration of 100 µM, the cells were pre-treated with ACV, chrysin 
and rivastigmine at a concentration of 2, 10, 50 µM each. The results show that 2 µM test drug concentration presented 
considerable protection, against STZ generated neurocytotoxicity via. restoration of anti-oxidant enzymes, MDA and AChE 
level, compared to the other two concentrations. 
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In the 20th century, unprecedented work pressure and a 
fast-pacing urban lifestyle made severe diseases, like 
diabetes, cardiovascular complications, respiratory 
illness, neurological disorders and cancer a widespread 
phenomenon. Cognitive impairments and loss of 
thinking ability, impaired neuronal communication and 
memory loss are the most common features of 
dementia. These prolonged symptoms collectively 
produced a loss of function and development of neuro 
defects in the geriatric population and are commonly 
referred to as Alzheimer's disease (AD). 
AD is a progressive neurodegenerative disorder 
characterized by psychological disabilities along with 
motor incoordination. However, in some families, AD 
is inherited as an autosomal dominant disorder of 
midlife. Usually, AD is recognized in the later stage 
when cognitive impairment appears1. In the literature, 
numerous models have been anticipated to explain 
tools and pathways regarding AD initiation. AD 
pathology included loss of cholinergic function, 
intracellular tau protein (microtubule-associated 
protein) hyperphosphorylation and extracellular β-
amyloid plaque formation2. AD faces two main 
challenges in the present scenario: delay in the 
diagnosis process and subsequently lack of target 
neuroprotective agent or curative pharmacological 
treatment.  
The formation of extracellular amyloid protein 
aggregation is the primary pathological indication of 
Alzheimer's pathology. In the brain, insulin is 
synthesized locally and transported via., a blood-brain 
barrier to peripheral circulation3. So the interruption 
in insulin signaling leads to learning and memory 
impairments4. Current reports supported the 
assumption that impaired brain insulin signaling, 
deregulation in energy and glucose utilization are 
important pathogenic causes of amyloid precursor 
protein (APP) processing5. Amyloid protein is the 
portion of the APP protein. When β and γ-secretase 
enzymes split APP protein unevenly, it produces the 








Like amyloid aggregation, tauopathy is another 
pathological indicator of AD. Microtubules associated 
protein tau gets hyperphosphorylated in the tauopathy 
condition and forms coiled paired helical filament 
(PHF) structures, known as neurofibrillary tangles 
(NFTs). These tangles are then accumulated 
intracellularly in the Alzheimer's brain7,8. 
These hallmarks, amyloid aggregation and 
tauopathy, both reduce the acetylcholine (ACh) 
neurotransmitter level considerably in AD. ACh is the 
leading neurotransmitter of the Central Nervous 
System (CNS), which plays a dynamic role in 
cognitive activity. During AD pathology, the ACh 
level drives downwards and ACh associated 
enzymatic activity of acetylcholinesterase (AChE) is 
enhanced cause the role of AChE is to break down the 
ACh into choline and acetate compound. Further, 
choline is re-uptaken by nerve terminals and reused 
for the synthesis of ACh neurotransmitters. The 
increased AChE activity demonstrated memory 
alteration and AD-like symptoms9. 
Coming to AD treatment, various medications are 
present globally, but they are short of being called a 
successful treatment against AD. Their benefits may 
vary from person to person, and there are many 
arguments among the researchers about the efficacy 
of current medications. The earlier animal studies 
have shown that polyphenols are effective against 
AD-like symptoms8. Therefore, we strive to confirm 
the effectiveness of polyphenols further by carrying 
out studies at the cellular level. 
In nature, flavonoids are the natural polyphenols 
present in plants and contain various pharmacological 
activities like anti-inflammatory, antiviral, anti-tumor 
and anti-oxidant activity10,11. Chrysin is a flavonoid 
compound found in honey and various plant extracts. 
Chrysin has reported various pharmacological 
activities like anti-allergic, antidiabetic, anticancer, 
anti-inflammatory and anti-oxidant properties11–15. 
Similarly, apple juice is one of the most consumed 
fruit juice in daily life. Apple Cider Vinegar (ACV) is 
produced from a cider that has undergone bioconversion 
procedures. It contains acetic acid, organic acids, 
flavonoids, polyphenols, vitamins and minerals but 
phenolic compounds are higher in concentration8,16,17. 
ACV comprises beneficial health effects for 
cardiovascular diseases like hyperlipidemia, 
hypercholesterolemia, diabetes, cancer and obesity17–20.  
Several experimental models using transgenic and 
non-transgenic animals have been used to study AD's 
dynamic outcomes21,22. In the rodent model, STZ 
administration via., an intracerebroventricular (ICV) 
route in the rat brain induces Alzheimer's like 
pathology23. Non-transgenic models consist of STZ23, 
β-amyloid24 and okadaic acid25 induced disease AD 
model on experimental rodents. So, the detailed 
effects of STZ on neuronal (N2A) cells is a  
novel experimental model for AD-like pathological  
markers like oxidative stress, tauopathy condition, 
amyloid aggregation, disrupted glucose uptake 
neuroinflammation, glial cell activation and 
deficiency in cholinergic activity.  
The current study was focused on the  
STZ-prompted oxidative stress on N2A cells. 
Therefore, the present study is designed to investigate  
STZ-prompted in vitro neurotoxicity on N2A cells 




The cell line work was performed in the Indian 
Institute of Technology (IIT), Kanpur from March to 
May 2019. In the in vitro experiment analysis, multiple 
duplicates of culture cells were prepared via., pipetting 
the equal volume of the cells. These culture samples 
were made from the same culture stock of cells. All the 
experiments had triplicate cultures and every experiment 
was performed three independent times.  
 




bromide (MTT) dye, Streptomycin-penicillin antibiotic 
solution, Dulbecco's modified Eagle's medium 
(DMEM), laboratory chemical like formaldehyde, 
Triton-X 100, streptozotocin (STZ), glutathione 
reductase, Nicotinamide Adenine dinucleotide 
phosphate (NADPH), Nicotinamide Adenine 
dinucleotide (NADH), ethylenediaminetetraacetic 
acid (EDTA), Xanthine oxidase (XOD), 
Thiobarbituric acid (TBA), Nitro-blue tetrazolium 
chloride (NBT), Trichloroacetic acid (TCA), Congo 
red, thioflavin-S dye 5,5’-dithiobis-2-nitrobenzoic 
acid (DTNB), 4’,6-diamidino-2-phenylindole dihydro 
chloride (DAPI), DPX (Dibutylphthalate Polystyrene 
Xylene), Acetylthiocholine iodide, chrysin and 
rivastigmine were procured from Sigma-Aldrich, 
USA. ACV was obtained from the manufacturing 
sources (The Unati Co-op Marketing-cum-processing 
Society Ltd., an ISO 22000:2005 certified company, 
Punjab). 




Cell culture & treatment 
Originally, Neuro2A (N2A) cells are derived from 
albino mouse brains, which reveal similar neuronal 
morphology characters, unlike other neuroblastoma 
cells26. This cell line was obtained from National 
Centre for Cell Sciences (NCCS) Pune, India and 
cultured in DMEM media with 10% fetal bovine 
serum (FBS) solution and 1% antibiotic solution. 
These cell lines were preserved in a humidified 
atmosphere (5% CO2 and 95% air) at 37°C. Once they 
reached 85% confluence, then they were used for 
further experiments. 
STZ was used to disrupt the insulin signaling in 
brain, leading to alteration of oxidative stress markers, 
induce amyloid pathogenesis and tauopathy27. So, in 
the current study, 100 µM concentration of STZ  
was used in N2A cells for 24 and 48 h to induced 
cellular toxicity and co-treatment with ACV, chrysin 
and rivastigmine at 2, 10, 50 µM concentrations  
(1 h before addition of STZ) were given to evaluate 
their effect on STZ induced cellular toxicity. 
 
Cell viability assay (MTT) 
The cell viability assay was conducted by using 
MTT dye to evaluate the cellular toxicity on the cells. 
The assay principle is to form violet formazan crystals 
in the viable cells by the division of tetrazolium salts 
in the presence of mitochondrial succinate reductase 
enzyme28. The N2A cell culture (1×106) containing 
DMEM media was seeded into a 96-well plate. After 
test drug treatments, the plate was placed within an 
incubator (37°C) for 24 and 48 h. After 24 and 48 h, 
MTT dye (0.5 mg/mL) solution was added to each 
well of the 96-well plate and plates were again 
incubated for 4 h. The supernatant was then discarded 
and 150 µL of fresh filtered DMSO was added  
to solubilize the formazan crystals. The color  
intensity was measured using a Spectra Max-3 
spectrophotometer plate reader at a wavelength of  
570 nm and calculation was performed via the 
following formula.  
 
100 Abs test – Abs blankPercentage of  cell viability
Abs control – Abs blank
( )  
Where, Abs = absorbance  
 
Estimation of Alzheimer's like pathological markers 
 
Thioflavin-S staining of cells (tauopathy) 
Thioflavin-S is a benzothiazole dye used to 
visualize hyperphosphorylated tau protein aggregation 
in both in vivo and in vitro experiments29. In the 
staining process, cells (1×106) were developed on 
gelatin-coated coverslips then exposed to STZ 
treatment at 100 µM concentration and test drug 
treatment at a 2 µM concentration. After 24 h 
incubation period, 4% formaldehyde solution was 
used to fix the cells on coverslips and washed once 
with PBS solution at room temperature. A solution of 
0.05% thioflavin-S dye in 50% ethanol was prepared 
to stain the cells. After staining the cells, three 
successive washes of 70% ethanol (5 min each), was 
given to the cells. At last, cells were counter stained 
with DAPI and mounted with glycerol to observe 
under a Y-TV55 Nikon fluorescence microscope. 
 
Congo red staining of cells (amyloid aggregation) 
Congo red dye was used for the validation of 
amyloid aggregation via bind with the Aβ plaques. 
So, this procedure was performed to detect 
extracellular amyloid plaque accumulation in the N2A 
cells30. In this procedure, the N2A cells (1×106) were 
developed on gelatin-coated coverslips and exposed 
to 100 µM concentration of STZ and 2 µM 
concentration of test drugs. After 24 h of the 
incubation period, 4% (v/v) formaldehyde solution 
was used to fix the cells on coverslips at room 
temperature and then the cells were washed one time 
with PBS solution. The alkaline Congo red solution 
was freshly prepared to stain the cells at room 
temperature. After staining, the cells were washed 
with deionized water (three washes) and mounted  





Reduced glutathione assay (GSH) 
Reduced GSH is an endogenous anti-oxidant, 
which is made during oxidative stress conditions. 
GSH enzyme protects against endogenous reactive 
oxygen species (ROS). GSH was determined by using 
an enzymatic method of Tietze et al.31 with certain 
modifications. Cells (1×106) were seeded on 30 mm 
Petri plates and incubated overnight before any 
treatment in this assay. After the incubation period, 
cells were washed with PBS solution and treated with 
10% trichloroacetic acid (TCA) solution. This cell 
mixture was centrifuged at 13,000 rpm for 1 min.  
To estimate the GSH level in the N2A cells, final  
1 mL reaction mixture volume contained 50 µL 
sample (supernatant), 0.1 M sodium phosphate buffer 
(pH 7.4), 1 unit/mL glutathione reductase, 5 mM 
EDTA solution, 0.6 mM DTNB and 0.2 mM  
β-NADPH solution. The absorbance was noted at  




412 nm and the following formula was used to 
calculate the GSH level.  
 
Reduced GSH Concentration =
Abs of  the test – Abs of  blank  × total volume of  assay
6.22×0.1
 
Where, 1= volume of the assay mixture 
6.22= Millimolar extinction coefficient of β-
NADPH 
0.1= enzyme volume  
 
Lipid peroxidation level (MDA) 
Oxidative stress leads to protein, lipid peroxidation 
and the aging process. MDA is the biomarker of lipid 
peroxidation. So any high increase in MDA level 
indicates low efficacy of the drug. MDA level was 
conducted by the process of Ohkawa et al.33. N2A 
cells were cultured on 30 mm Petri plates with 1×106 
cells/mL concentration and were treated with STZ 
(100 µM) and test drugs with 2, 10 µM concentration. 
After the subjective treatment of test drugs, cells were 
incubated for 24 h. The cells were then washed with 
PBS solution and lysed in 1% KCl with 1% Triton  
X-100 solution by sonication for 5 min. Then 100 µL 
of cell lysate solution was taken and mixed with  
200 µL of 8.1% SDS solution, 1.5 mL of 20% acetic 
acid (pH 3.5), 1.5 mL of 0.8% thiobarbituric acid 
(TBA) solution, and final 4 mL volume were made 
using deionized water. The reaction mixture was 
boiled on a water bath for 2 h for color development 
(pink color), followed by the cooling process. This 
mixture was centrifuged at 3000 rpm (10 min) and the 
supernatant absorbance was read at 532 nm. The 
MDA content was calculated using the following 
formula34. 
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Where, 1.56×105= molar extinction coefficient in  
M-1 cm-1 
 
Superoxide dismutase assay (SOD) 
SOD enzymatically scavenges superoxide 
generated by oxidative stress. So SODs constitute the 
first line of defense against ROS' deleterious effects in 
neurodegenerative disorders like Alzheimer's disease. 
N2A cells (1×106) were seeded on 30 mm Petri plates 
and incubated overnight before any treatment. For 
trypsinization of adherent cells, 0.2% (w/v) EDTA 
and 0.5% (w/v) trypsin solution were used. Then 
pellet of the cells was mixed with 500 µL of 1X cell 
lysis solution. It was mixed thoroughly and the 
process was repeated. This cell suspension solution 
was centrifuged for 5 min at 14000 rpm at 4°C.  
The supernatant was placed in a clean Eppendorf tube 
(1.5 mL) and stored at -80°C for further analysis. The 
total reaction volume of the SOD assay was 1.5 mL 
(540 µL reagent components and 960 µL deionized 
water). The reaction mixture contained 30 µL of 
nitroblue tetrazolium (NBT) solution, 200 µL of 
NADH solution and 10 µL of xanthine oxidase 
(XOD) solution and 300 µL cell lysate solution35. The 
reduction of NBT to blue formazan crystals was 
measured at 560 nm under aerobic conditions and the 
following formula was used to measure enzyme 
activity36. 
 
Abs of  Control - Abs of  TestPercentage Inhibition  = ×100
Abs of  Control
 
 
Acetylcholinesterase activity (AChE) 
AChE assay was assessed using the mode defined 
by Ellman et al.37 with specific alterations. In this 
method, the N2A cells were seeded in 35 mm Petri 
plates and incubated overnight before test drug 
treatments. The treatment of 100 µM concentration of 
STZ was given in N2A cells, and co-treatment with 
test drugs (2,10 µM) was given 1 h before the 
addition of STZ and incubated for 24 h. After 24 h of 
incubation, cells were lysed in cold 0.1 M sodium 
phosphate buffer (pH 7.8) with a 0.1% Triton-X 100 
solution by sonication. This cell lysed solution was 
centrifuged at 10,000 rpm (20 min) at 4°C and the 
supernatant solution was used for AChE activity. The 
reaction mixture contains 10 µL of cell supernatant, 
2.8 mL assay buffer, 0.1 mL of DTNB (10 mM) and 
20 µL of acetylthiocholine iodide (100 mM) solution 
were mixed well. The kinetic profile was measured at 
412 nm for 2 min at 15 sec intervals using a Spectra-
max-3spectrophotometer. 
 
Abs of  control – Abs of  testPercentage Inhibition = × 100




The present study data were evaluated by using 
ANOVA (One-way) followed by using Tukey's 
Multiple Comparison Test. Graph Pad Prism version 
5 software was used for three independent 
experiments (n=3) to analyze the data. A p-value less 
than 0.05 was considered statistically significant and 
all the data were expressed as Mean±SD. 






Cell viability assay (MTT) 
STZ treatment showed significant (p<0.05) 
differences in mitochondrial dehydrogenase activity. 
The cell viability of STZ (100 μM) treated cells was 
found 72.4%, 64.3%, respectively, after 24 h and 48 
h. Co-treatment of chrysin with STZ-treated cells 
showed cell viability to be 80%, 42.8% and 21.7% 
after 24 h and 90.7%, 32.37% and 1.66% after 48 h at 
2, 10, 50 μM concentrations respectively. Similarly 
cell viability of ACV with STZ treatment was found 
to be 91.4%, 82.3% and 50.5% after 24 h and 93.3%, 
77,3% and 44.5% after 48 h at 2, 10, 50 μM 
concentrations, respectively. Cell viability of 
rivastigmine with STZ-treated cells were found 
82.3%, 64.7% and 39% after 24 h and 76.2%, 31.8% 
and 29.2% after 48 h at 2, 10, 50 μM concentrations, 
respectively. Cell viability assay results concluded 
that ACV showed more protection to N2A cells than 
chrysin and rivastigmine treatment (Fig. 1a, b).  
 
Quantitative analysis of Alzheimer's related pathological 
markers 
 
Thioflavin-S staining of cells 
Intracellular neurofibrillary tangles (NFTs) are the 
critical neuropathological feature of AD. In the AD 
pathology, abnormally phosphorylated tau protein 
made paired helical filaments (PHFs), which lead to 
the development of NFTs. This thioflavin-S dye 
displays green fluorescence due to the presence of 
PHFs in STZ-treated N2A cells. A significant 
(p<0.001) increase in green color fluorescence was 
found in STZ-treated cells compared with control 
cells. Co-treatment with test drugs showed significant 
(chrysin and rivastigmine, p<0.01 and ACV, p<0.05) 
reduction in green color fluorescence compared with 
STZ-treated cells. In the test groups, ACV showed 
better protection of cells against STZ-induced 
tauopathy than the other two drugs. The observations 
are reported at a 2 µM concentration of test drugs 
with STZ (100 µM) treatment (Fig. 2a). 
 
Congo red staining in cells 
Congo red staining process was performed in N2A 
cells for the detection of the extracellular amyloid 
plaque development. The STZ treatment displayed  
a significant (p<0.001) increase in red-stained at  
100 µM concentration compared to control cells. Co-
treatment with test drugs showed significant (chrysin 
and rivastigmine, p<0.05 and ACV, p<0.01) reduction 
in red-stained compared with STZ-treated cells. Co-
treatment of test drugs at 2 µM concentration offers 
an effective defense against STZ induced amyloid 
accumulation (Fig. 2b). 
 
Assessment of anti-oxidant activity of cells 
The cellular anti-oxidant activity of SOD and GSH 
enzymes declined significantly (p<0.05) in the STZ-
treated group by 24.83% and 52.91%, respectively, at 
100 µM concentration after 24 h as compared to 
control cells. Co-treatment with test drug chrysin 
showed a significant (p<0.001, p<0.01) increase in the 
SOD and GSH level as 43.35% and 74.4% after 24 h 
at 2 μM concentrations as compared with STZ-treated 
 
 
Fig. 1(a, b) — Graphical representation of Cell viability assay
of STZ (100 µM) treatment and STZ+Drugs (2,10,50 µM
concentrations) treatment, after 24 and 48 h. Data are represented
as Mean±SD, analyzed by one-way ANOVA, Tukey's Multiple
Comparison Test of three independent experiments. *p<0.05 STZ-
treated cells vs. Control cells. #p<0.05, ##p<0.01, ###p<0.001
STZ+Drugs vs STZ-treated cells. 
 
 
Fig. 2(a, b) — Graphical representation of Thioflavin-S 
(Fluorescent intensity) and Congo red-stained cells in N2A cells. 
Data are represented as Mean±SD, analyzed by one-way 
ANOVA, Tukey's Multiple Comparison Test of three independent
experiments. ***p<0.001 STZ-treated cells vs. Control cells. 
#p<0.05, ##p<0.01 STZ+Drugs vs STZ-treated cells. 




cells. Similarly, co-treatment with ACV (p<0.05) and 
rivastigmine (p<0.01) displayed a significant increase 
in the levels of SOD and GSH and the percentage 
increase was 68.75%, 84% for ACV and 50.47%, 
76% for rivastigmine after 24 h at 2 μM 
concentrations as compared with STZ-treated cells 
(Fig. 3a,b). The results indicated a reduction in GSH 
level and SOD activity was improved by pre-
treatment with chrysin, ACV and rivastigmine but not 
up to the control level.  
STZ exposure in N2A cells also leads to lipids' 
peroxidation, which was measured by MDA level. N2A 
cells were exposed to 100 µM concentration of STZ 
showed a significant (p<0.05) increase in MDA level up 
to 232.68% after 24 h compared to control cells.  
Pre-treatment with chrysin, ACV and rivastigmine 
significantly declined in MDA level. The reduction  
in MDA level were as follows, for chrysin 
(p<0.01,126.82%), ACV(p<0.05, 111.54%) and 
rivastigmine (p<0.001, 152.75%) after 24 h at 2 μM 
concentration as compared to STZ-treated cells (Fig. 3c). 
 
AChE activity 
A significant increase (p<0.05) was found in the 
AChE activity of the STZ-treated N2A cells. The 
increased AChE activity was found to be 193.91%  
at 100 μM concentration of the STZ-treated group 
compared to control cells. Protection of N2A cells on 
pre-treatment with chrysin, ACV and rivastigmine 
significantly decreased AChE level, and percentage 
decrease was as follows for chrysin (p<0.01, 129.91%), 
ACV (p<0.05, 117.88%) and rivastigmine (p<0.01, 
139.20%) respectively after 24 h at 2 μM concentration 
in comparison to STZ-treated cells (Fig. 4). 
 
Discussion 
The previous reports explained that STZ 
administration in rodents is a well-established model 
of dementia23,38,39. However, this specific action of 
STZ on neuronal cells was yet to be explored. Our in 
vitro exploration would provide the idea to identify 
Alzheimer's like physiological features at the neuronal 
cell level. So present study indicates the outline of 
STZ-induced cytotoxicity in N2A cells. In this study, 
dose selection of STZ was made according to 
previous studies, and the percentage of cell viability 
 
 
Fig. 3(a,b,c) — SOD, reduced GSH and MDA activity of STZ
(100 µM) treatment and STZ+Drugs (2,10 µM concentration)
treatment, after 24h. Data are represented as Mean±SD, analyzed by
one-way ANOVA, Tukey's Multiple Comparison Test of three
independent experiments. *p<0.05 STZ-treated cells vs. Control cells.
#p<0.05, ##p<0.01, ###p<0.001 STZ+Drugs vs STZ-treated cells. 
 
 
Fig. 4 — Graphical representation of AChE activity of STZ
(100 µM concentration) treatment and STZ+Drugs (2,10 µM
concentration) treatment, after 24 h. Data are represented as
Mean±SD analyzed by one-way ANOVA, Tukey's Multiple
Comparison Test of three independent experiments. *p<0.05 STZ-
treated cells vs. Control cells. #p<0.05, ##p<0.01 STZ+Drugs vs
STZ-treated cells. 




was measured by cell viability (MTT) assay  
(Fig. 1a,b) after the optimum dose of STZ treatment27. 
In this study, pathological markers of AD-like  
tau hyperphosphorylation (tauopathy), β amyloid 
accumulation, AChE activity and anti-oxidant activity 
were assessed in the N2A cells after STZ treatment. 
Tau phosphorylation is the prominent indicator of 
AD, which was evaluated by thioflavin-S staining. 
Various kinase enzymes like GSK-3β and MAPK are 
responsible for the hyperphosphorylation of tau 
protein to forms NFTs40,41. The results indicated that 
STZ treatment caused a high proportion of NFTs 
formation in STZ-treated cells (Fig. 2a). Our results 
complement the finding of animal studies42. 
Further, amyloid aggregation was evaluated by 
Congo red staining procedure (Fig. 2b). This dye 
stained the extracellular protein aggregation (amyloid) 
present in STZ-treated neuronal cells27. So from the 
evaluation of staining results, it is clear that STZ 
treatment induced tauopathy and amyloid aggregation 
in the cells.  
The STZ treatment on neuronal cells produces 
impaired insulin signaling and depletion of glucose 
utilization43,44. STZ treatment also creates oxidative 
stress estimated by anti-oxidant activity like SOD, 
GSH and MDA levels. The two major causes of 
oxidative stress are either excessive production of 
ROS or decreased cellular anti-oxidant levels like 
SOD and GSH45. SOD and reduced glutathione 
(GSH) plays a significant role in a physiological anti-
oxidant and are important free radical scavenger to 
protect the cells. Reduction in GSH level initiates 
peroxidation of proteins, lipids, carbohydrates and 
DNA injury, introducing neuronal toxicity and also 
causes neuronal cell death. The biomarker of 
oxidative stress is lipid peroxidation (MDA). 
Peroxidation of lipids leads to the production of 
Malondialdehyde. Observations indicate that STZ 
increased lipid peroxidation (MDA) level and reduced 
the physiological anti-oxidants (GSH and SOD) level 
in N2A cells (Fig. 3a-c). 
Another pathological marker of AD is the death of 
neurons associated with the cholinergic system, which 
is the most acceptable AD-like pathology hypothesis. 
The reduction in acetylcholine level triggers a decline 
in neurotransmission and induces propagation  
of dementia-linked AD-like symptoms. So AChE 
activity was also assessed in cells (Fig. 4). The 
treatment of STZ induces an increase in AChE 
activity, which directed the decrease in acetylcholine 
level, showing that STZ treatment has produced 
cholinergic cell death in N2A cells.  
Further, to verify the outcome of STZ-induced 
neurotoxicity, the effect of test drugs chrysin, ACV 
and Anti Alzheimer's medication rivastigmine was 
assessed on N2A cells. Pre-treatment of test drugs 
showed significant protection and restored the 
biochemical parameters that were altered by STZ 
treatment. The existence of phenolic compounds in 
the ACV and chrysin produced protective effects due 
to various pharmacological activity8,17. The test drugs 
have reduced tau phosphorylation, amyloid deposition 
and enhanced the SOD, GSH activity compared to 
STZ-treated cells. They have also reduced MDA and 
AChE levels, thus maintaining the anti-oxidant level 
compared to STZ-treated cells but not up to the 
control level. The pre-treatment of test drugs at 2 µM 
concentration reported the most significant protection 
against cellular toxicity, tau phosphorylation and 
amyloid staining and also restored the anti-oxidants 
markers of N2A cells.  
 
Conclusion 
All the results of in vitro study showed that 
polyphenols have curative abilities against AD-like 
markers. ACV produced more operative results 
compared with chrysin and rivastigmine. In 
conclusion, the outcome suggests that the 
neuroprotective effect of ACV is mainly associated 
with the modification of the cholinergic neuronal 
system and the modulation of oxidative stress. ACV 
has protected N2A cells from neurotoxicity and 
reduced the formation of NFTs and amyloid 
aggregation. Therefore, our observations at the 
cellular level support the claims of prior animals 
studies that ACV may have curative potential toward 
AD. For future research, we would recommend 
further studies at molecular levels to uncover intricate 
protective mechanisms.  
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